| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
(NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and comm...
Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target ...
Truist Securities analyst Danielle Brill maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price targe...
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ: PVLA) with a Buy and raises the price targe...
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ: PVLA) with a Buy and raises the pric...
Stifel analyst Annabel Samimy maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $60 ...
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and signi...
